We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Apellis Pharmaceuticals' (APLS) Q3 Loss Wider Than Expected
Read MoreHide Full Article
Apellis Pharmaceuticals Inc. (APLS - Free Report) reported a loss of $1.79 per share in the third quarter of 2020. The loss was wider than the year-ago quarter’s loss of $1.10 per share and the Zacks Consensus Estimate of a loss of $1.53.
With no approved drug in its portfolio, the company does not generate any revenue from the sale of products. However, it incurred licensing revenues of $0.65 million.
Shares of the company have decreased 2.2% compared with the industry’s decline of 8.0%.
Quarter in Detail
Research and development (R&D) expenses were $93.2 million in the third quarter of 2020 compared with$51.3 million for the same period in 2019.
General and administrative expenses were $37 million in the third quarter of 2020 compared with $18.6 million for the same period in 2019.
Pipeline Update
In September 2020, Apellis submitted a new drug application (NDA) to the FDA and a marketing authorization application (MAA) to the European Medicines Agency (EMA) for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The FDA’s filing decision on the NDA is expected in the fourth quarter of 2020. . An opinion from the Committee for Medicinal Products for Human Use (CHMP) is expected in 2021.
The company expects to report 48-week top-line results from the PEGASUS study by the end of 2020 and top-line results from the phase III PRINCE study in patients with PNH who are treatment-naïve in the first half of 2021.
Zacks Rank and Stocks to Consider
Apellis currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Emergent BioSolutions Inc. (EBS - Free Report) , ADC Therapeutics SA (ADCT - Free Report) and Bellus Health, Inc. . While Emergent sports a Zacks Rank #1 (Strong Buy), ADC Therapeutics and Bellus Health carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have increased from $5.31 to $6.61 for 2020 and from $6.06 to $8.42 for 2021 over the past 90 days. Shares of the company have increased 68.8% year to date.
ADC Therapeutics’ loss per share estimates have narrowed from $4.37 to $4.32 for 2020 and from $3.19 to $3.08 for 2021 in the past 60 days. Shares of the company have decreased 2.2% year to date.
Bellus’loss per share estimates have narrowed from 71 cents to 62 cents for 2020 and from 88 cents to 79 cents in the past 90 days. Shares of the company have decreased 69.2% year to date.
Apellis Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027. Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
Apellis Pharmaceuticals' (APLS) Q3 Loss Wider Than Expected
Apellis Pharmaceuticals Inc. (APLS - Free Report) reported a loss of $1.79 per share in the third quarter of 2020. The loss was wider than the year-ago quarter’s loss of $1.10 per share and the Zacks Consensus Estimate of a loss of $1.53.
With no approved drug in its portfolio, the company does not generate any revenue from the sale of products. However, it incurred licensing revenues of $0.65 million.
Shares of the company have decreased 2.2% compared with the industry’s decline of 8.0%.
Quarter in Detail
Research and development (R&D) expenses were $93.2 million in the third quarter of 2020 compared with$51.3 million for the same period in 2019.
General and administrative expenses were $37 million in the third quarter of 2020 compared with $18.6 million for the same period in 2019.
Pipeline Update
In September 2020, Apellis submitted a new drug application (NDA) to the FDA and a marketing authorization application (MAA) to the European Medicines Agency (EMA) for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The FDA’s filing decision on the NDA is expected in the fourth quarter of 2020. . An opinion from the Committee for Medicinal Products for Human Use (CHMP) is expected in 2021.
The company expects to report 48-week top-line results from the PEGASUS study by the end of 2020 and top-line results from the phase III PRINCE study in patients with PNH who are treatment-naïve in the first half of 2021.
Zacks Rank and Stocks to Consider
Apellis currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Emergent BioSolutions Inc. (EBS - Free Report) , ADC Therapeutics SA (ADCT - Free Report) and Bellus Health, Inc. . While Emergent sports a Zacks Rank #1 (Strong Buy), ADC Therapeutics and Bellus Health carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Emergent’s earnings estimates have increased from $5.31 to $6.61 for 2020 and from $6.06 to $8.42 for 2021 over the past 90 days. Shares of the company have increased 68.8% year to date.
ADC Therapeutics’ loss per share estimates have narrowed from $4.37 to $4.32 for 2020 and from $3.19 to $3.08 for 2021 in the past 60 days. Shares of the company have decreased 2.2% year to date.
Bellus’loss per share estimates have narrowed from 71 cents to 62 cents for 2020 and from 88 cents to 79 cents in the past 90 days. Shares of the company have decreased 69.2% year to date.
Apellis Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Apellis Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Apellis Pharmaceuticals, Inc. Quote
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027. Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>